Prof Bieber opened the symposium by explaining that there has been a revolution in the management of patients with moderate-to-severe atopic dermatitis (AD) since the approval of the first biologic, dupilumab, in 2017.
Dermatology
Login to continue
Members
Create Account
Create your own personal healthcare feed, full of the latest content from across our divisions.
Register
